KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis

Chenyue Zhang¹, Chenxing Zhang², Jia Li³, Haiyong Wang⁴

Affiliations

¹ Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, People's Republic of China.
² Department of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
³ Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
⁴ Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China. Electronic address: wanghaiyong6688@126.com.

PMID: 32471565
DOI: 10.1016/j.jtho.2020.02.027

Free article

Comment

KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis

Chenyue Zhang et al. J Thorac Oncol. 2020 Jun.

Free article

. 2020 Jun;15(6):e85-e86.

doi: 10.1016/j.jtho.2020.02.027.

Authors

Chenyue Zhang¹, Chenxing Zhang², Jia Li³, Haiyong Wang⁴

Affiliations

¹ Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, People's Republic of China.
² Department of Nephrology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
³ Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
⁴ Department of Internal Medicine Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China. Electronic address: wanghaiyong6688@126.com.

PMID: 32471565
DOI: 10.1016/j.jtho.2020.02.027

No abstract available

PubMed Disclaimer

Comment in

KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis".
Mazzotta M, Marinelli D, Maugeri-Saccà M. Mazzotta M, et al. J Thorac Oncol. 2020 Jun;15(6):e87-e88. doi: 10.1016/j.jtho.2020.03.024. J Thorac Oncol. 2020. PMID: 32471566 No abstract available.

Comment on

Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F, De Nicola F, Scalera S, Sperati F, Gallo E, Ciuffreda L, Pallocca M, Pizzuti L, Krasniqi E, Barchiesi G, Vici P, Barba M, Buglioni S, Casini B, Visca P, Pescarmona E, Mazzotta M, De Maria R, Fanciulli M, Ciliberto G, Maugeri-Saccà M. Goeman F, et al. J Thorac Oncol. 2019 Nov;14(11):1924-1934. doi: 10.1016/j.jtho.2019.07.003. Epub 2019 Jul 16. J Thorac Oncol. 2019. PMID: 31323387

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis

Affiliations

KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis

Authors

Affiliations

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical